Savara (NASDAQ:SVRA) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.
Several other equities research analysts have also recently weighed in on SVRA. BidaskClub upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research cut shares of Savara from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd. Roth Capital lowered their price objective on shares of Savara from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, October 31st. Ladenburg Thalmann Financial Services began coverage on shares of Savara in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Canaccord Genuity raised their price objective on shares of Savara from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $23.58.
Savara (SVRA) traded up $0.91 on Wednesday, reaching $13.41. 192,951 shares of the company’s stock traded hands, compared to its average volume of 172,125. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The firm has a market cap of $361.43, a PE ratio of -3.20 and a beta of -0.26. Savara has a 52-week low of $4.60 and a 52-week high of $17.19.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Upgrades Savara (SVRA) to “Sell”” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/valuengine-upgrades-savara-svra-to-sell.html.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.